VCEL
Vericel Corporation
A biopharmaceutical company that grows patients' own cells into treatments for sports injuries and severe burns. Its flagship product, MACI, repairs torn knee cartilage, while Epicel grows a patient's skin cells into a permanent graft for large burns. Founded in 1989 as Aastrom Biosciences, it became Vericel in 2014 after buying Sanofi's cell-therapy business. The name plays on the word "cell," and thousands of burn patients have been treated with Epicel.
CUSIP: 92346J108HealthcareUS
No tracked superinvestors held this security in this period.
Superinvestor entry prices
Estimated from filings — the split-adjusted price range over the quarters each manager built the position. A range, not a fill price; 13F reports a quarter-end snapshot, not a trade date.
Investor
Est. entry (range)
Today
Mairs & Power+115% vs entry
entry $19.02 ($13.40–$32.00)